Journey Medical (DERM) Scheduled to Post Earnings on Monday

Journey Medical (NASDAQ:DERM) will be posting its quarterly earnings results after the market closes on Monday, May 13th. Analysts expect Journey Medical to post earnings of ($0.26) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.12) earnings per share (EPS) for the quarter. Journey Medical had a negative return on equity of 34.08% and a negative net margin of 4.87%. The company had revenue of $15.26 million for the quarter, compared to analysts’ expectations of $15.80 million. On average, analysts expect Journey Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Journey Medical Price Performance

NASDAQ DERM opened at $3.51 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.10 and a current ratio of 1.35. Journey Medical has a 52-week low of $1.02 and a 52-week high of $8.11. The business’s 50-day moving average is $3.65.

Wall Street Analyst Weigh In

Separately, Alliance Global Partners began coverage on shares of Journey Medical in a research report on Friday, February 16th. They issued a “buy” rating and a $8.50 price objective for the company.

Insider Activity

In related news, Director Lindsay A. Md Rosenwald acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was purchased at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the transaction, the director now directly owns 144,245 shares of the company’s stock, valued at approximately $438,504.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Lindsay A. Md Rosenwald bought 10,000 shares of the stock in a transaction on Monday, March 25th. The stock was purchased at an average cost of $3.04 per share, with a total value of $30,400.00. Following the purchase, the director now owns 144,245 shares of the company’s stock, valued at $438,504.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Justin Adam Smith bought 30,000 shares of the stock in a transaction on Friday, March 22nd. The stock was purchased at an average cost of $3.47 per share, with a total value of $104,100.00. Following the completion of the purchase, the director now directly owns 134,717 shares in the company, valued at approximately $467,467.99. The disclosure for this purchase can be found here. In the last three months, insiders purchased 50,000 shares of company stock worth $169,300. Company insiders own 19.42% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.